News & Views

|
News, Press Release
|
Category: News, Press Release

Anova Expands Platform with Launch of Next-Generation eTMF Solution for Sponsors, CROs, and Research Sites

July 21, 2026|Anova|News, Press ReleaseJuly 21, 2026Category: News, Press Release Next-generation AnovaOS document management, incorporating eTMF platform that combines eISFs, automated document completion and trial master file maintenance, workflow management, integrated eSignature, and in a single unified clinical operations environment Platform is free for investigative sites, accelerating adoption while reducing administrative burden for sponsors, CROs, and sites The 21 CFR…
|
News, Press Release
|
Category: News, Press Release

Anova and Nouveau Biosciences Announce Partnership to Deliver Clinical Trials of Kromastat for the Treatment of Relapsed or Refractory Cutaneous and Peripheral T-Cell Lymphoma

Anova today announced its partnership with Nouveau Biosciences, Inc. to conduct cancer focused clinical trials for their lead asset Kromastat. Nouveau Biosciences is a biotechnology company pioneering novel targeted nanomedicines to improve cancer therapy.
|
News, Press Release
|
Category: News, Press Release

Five Hundredth Urology Research Site Joins Anova’s Global Urology Research Network

Anova today announced the expansion of a virtual urology research network delivered via its AnovaOS platform. This network of quality confirmed urology research sites has reached a major milestone with the onboarding of its 500th site. Anova’s proprietary clinical research technology platform, AnovaOS‚ facilitates seamless collaboration, streamlined study operations, and enhanced patient access across complex clinical trial settings.
|
News, Press Release
|
Category: News, Press Release

Anova launches global clinical registry to accelerate research and access to promising new treatments

Anova has announced the launch of a global clinical registry to accelerate the development of promising new treatments. The 21 CFR Part 11 compliant AnovaOS® global clinical registry provides a rich source of real-world evidence about research sites and patients, administrative efficiency in the conduct of research, a tool for post-market surveillance, and information to support data-driven study design, with…
|
News, Press Release, Views
|
Category: News, Press Release, Views

Anova Announces First Patient Enrolled to Phase 1/2a Study of DB107 for the Treatment of High-Grade Gliomas

Anova has announced enrollment of the first two patients in the highly anticipated study of DB107 for the treatment of brain tumors. The Phase 1/2a clinical trial is a multicenter, open-label study designed to confirm whether treatment DB107, when added to standard-of-care (SOC), provides clinical benefit to patients with newly diagnosed high-grade gliomas (HGG) when compared to historical performance.
|
Press Release
|
Category: Press Release

Anova Expands Leadership Team to Manage Growth and Drive Innovation

Anova proudly announces the appointment of Fred Ma, MD, PhD, Adam Callahan, MBA, and Rhonda Rosen, MBA, CPA., to key executive roles. The expansion of Anova’s leadership team reflects the companies significant growth, and adds decades of transformative leadership in the pharmaceutical, biotechnology, and medical device industries, to Anova’s leadership team. 
|
News, Press Release
|
Category: News, Press Release

Anova to Manage Study of DB107 Following Newly Awarded $11.8m CIRM Grant

Anova, a technology enabled CRO dedicated to accelerating promising treatments, has collaborated with University of California at San Francisco (UCSF), University of California at San Diego (UCSD), the University of Southern California (USC) and Denovo Biopharma to manage a newly awarded $11.8M California Institute for Regenerative Medicine (CIRM) grant to support the development of DB107 in patients with newly diagnosed…

Register today, connect your research network, 
and accelerate your research program.

Up arrow